Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis.
Cabergoline resistant
Dopamine Agonist (DA) resistant
Dopamine Agonist intolerant
Medically Failed Prolactinoma
Prolactinoma
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
accepted:
16
09
2021
pubmed:
29
9
2021
medline:
18
1
2022
entrez:
28
9
2021
Statut:
ppublish
Résumé
In Prolactinomas, surgery or radiation are reserved for DA failure due to tumor resistance, intolerance to medication-induced side-effects, or patient preference. This systematic review and meta-analysis summarizes the currently available literature regarding the effectiveness of surgery to treat prolactinomas in patients who have failed DA therapy. A literature search was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for studies that reported outcomes of medically resistant and intolerant prolactinoma treated surgically. 10 articles (Total N = 816, Surgery N = 657) met the inclusion criteria. 38% of patients who underwent surgery following DA failure achieved remission without need for further treatment (p < 0.001, I This systematic review and meta-analysis revealed 38% of operated patients achieved remission, while 62% achieved remission when additional modes of therapy were implemented. Therefore, although surgery has not been initial therapeutic choice for prolactinoma, it plays a significant role in medically failed prolactinoma care.
Identifiants
pubmed: 34580821
doi: 10.1007/s11102-021-01188-7
pii: 10.1007/s11102-021-01188-7
doi:
Substances chimiques
Dopamine Agonists
0
Prolactin
9002-62-4
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
978-988Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Vroonen L, Daly AF, Beckers A (2019) Epidemiology and management challenges in prolactinomas. Neuroendocrinology 109(1):20–27. https://doi.org/10.1159/000497746
doi: 10.1159/000497746
pubmed: 30731464
Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8(1):3–6. doi: https://doi.org/10.1007/s11102-005-5079-0
doi: 10.1007/s11102-005-5079-0
pubmed: 16411062
Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288. https://doi.org/10.1210/jc.2010-1692
doi: 10.1210/jc.2010-1692
pubmed: 21296991
Ono M, Miki N, Kawamata T et al (2008) Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93(12):4721–4727. doi: https://doi.org/10.1210/jc.2007-2758
doi: 10.1210/jc.2007-2758
pubmed: 18812485
Webster J (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14(4):228–238. https://doi.org/10.2165/00002018-199614040-00003
doi: 10.2165/00002018-199614040-00003
pubmed: 8713691
Colao A, Vitale G, Cappabianca P et al (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89(4):1704–1711. https://academic.oup.com/jcem/article-abstract/89/4/1704/2844342
doi: 10.1210/jc.2003-030979
Webster J, Piscitelli G, Polll A et al. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin Endocrinol. 1993;39(3):323–329. https://onlinelibrary.wiley.com/doi/abs/ https://doi.org/10.1111/j.1365-2265.1993.tb02372.x
doi: 10.1111/j.1365-2265.1993.tb02372.x
Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G (2002) Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11(6):787–800. doi: https://doi.org/10.1517/13543784.11.6.787
doi: 10.1517/13543784.11.6.787
pubmed: 12036422
Serri O, Beauregard H, Lesage J et al (1990) Long term treatment with CV 205–502 in patients with prolactin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 71(3):682–687. doi: https://doi.org/10.1210/jcem-71-3-682
doi: 10.1210/jcem-71-3-682
pubmed: 2394774
Delgrange E, Crabbé J, Donckier J (1998) Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res 49(5):250–253. doi: https://doi.org/10.1159/000023180
doi: 10.1159/000023180
pubmed: 9568811
Molitch ME (2003) Dopamine resistance of prolactinomas. Pituitary 6(1):19–27. doi: https://doi.org/10.1023/a:1026225625897
doi: 10.1023/a:1026225625897
pubmed: 14674720
Molitch ME (2005) Pharmacologic resistance in prolactinoma patients. Pituitary 8(1):43–52. doi: https://doi.org/10.1007/s11102-005-5085-2
doi: 10.1007/s11102-005-5085-2
pubmed: 16411068
Souteiro P, Karavitaki N (2020) Dopamine agonist resistant prolactinomas: any alternative medical treatment? Pituitary 23(1):27–37. doi: https://doi.org/10.1007/s11102-019-00987-3
doi: 10.1007/s11102-019-00987-3
pubmed: 31522358
Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109(1):42–50. https://doi.org/10.1159/000495775
doi: 10.1159/000495775
pubmed: 30481756
Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534. doi: https://doi.org/10.1210/er.2005-9998
doi: 10.1210/er.2005-9998
pubmed: 16705142
Bolko P, Jaskuła M, Waśko R, Wołuń M, Sowiński J (2003) The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type. Pol Arch Med Wewn 109(5):489–495. https://www.ncbi.nlm.nih.gov/pubmed/14768178
pubmed: 14768178
Menucci M, Quiñones-Hinojosa A, Burger P, Salvatori R (2011) Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14(1):68–74. doi: https://doi.org/10.1007/s11102-010-0261-4
doi: 10.1007/s11102-010-0261-4
pubmed: 20878243
pmcid: 4612584
Iglesias P, Díez JJ (2013) Macroprolactinoma: a diagnostic and therapeutic update. QJM 106(6):495–504. doi: https://doi.org/10.1093/qjmed/hcs240
doi: 10.1093/qjmed/hcs240
pubmed: 23329574
Oh MC, Aghi MK (2011) Dopamine agonist-resistant prolactinomas. J Neurosurg 114(5):1369–1379. doi: https://doi.org/10.3171/2010.11.JNS101369
doi: 10.3171/2010.11.JNS101369
pubmed: 21214334
Casanueva FF, Molitch ME, Schlechte JA et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 65(2):265–273. https://doi.org/10.1111/j.1365-2265.2006.02562.x
doi: 10.1111/j.1365-2265.2006.02562.x
Araujo-Castro M, López AA, Pardo JA, Kanaan LK, Palacios García N (2020) Phenotype and resistance patterns of 10 resistant prolactinomas. Endocrinol Diabetes Nutr 67(3):194–204. https://doi.org/10.1016/j.endinu.2019.04.007
doi: 10.1016/j.endinu.2019.04.007
Donegan D, Atkinson JLD, Jentoft M et al (2017) Surgical outcomes of prolactinomas in recent era: results of a heterogenous group. Endocr Pract 23(1):37–45. https://doi.org/10.4158/EP161446.OR
doi: 10.4158/EP161446.OR
pubmed: 27682355
Kreutzer J, Buslei R, Wallaschofski H et al (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158(1):11–18. doi: https://doi.org/10.1530/EJE-07-0248
doi: 10.1530/EJE-07-0248
pubmed: 18166812
Smith TR, Hulou MM, Huang KT et al (2015) Current indications for the surgical treatment of prolactinomas. J Clin Neurosci 22(11):1785–1791. doi: https://doi.org/10.1016/j.jocn.2015.06.001
doi: 10.1016/j.jocn.2015.06.001
pubmed: 26277642
Primeau V, Raftopoulos C, Maiter D (2012) Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol 166(5):779–786. doi: https://doi.org/10.1530/EJE-11-1000
doi: 10.1530/EJE-11-1000
pubmed: 22301915
Iuliano SL, Bi WL, Laws ER (2021) Changes in the options for management of prolactin secreting pituitary adenomas. J Neurol Surg B Skull BaseDoi. https://doi.org/10.1055/s-0040-1722665
doi: 10.1055/s-0040-1722665
Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F et al (2020) Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgz144
doi: 10.1210/clinem/dgz144
pubmed: 32480408
pmcid: 7823264
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8(5):336–341. doi: https://doi.org/10.1016/j.ijsu.2010.02.007
doi: 10.1016/j.ijsu.2010.02.007
pubmed: 20171303
Ottawa Hospital Research Institute. Accessed April 17 (2021) http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
Atkins D, Best D, Briss PA et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490. doi: https://doi.org/10.1136/bmj.328.7454.1490
doi: 10.1136/bmj.328.7454.1490
pubmed: 15205295
Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. doi: https://doi.org/10.1136/bmj.327.7414.557
doi: 10.1136/bmj.327.7414.557
pubmed: 12958120
pmcid: 12958120
Akin S, Isikay I, Soylemezoglu F, Yucel T, Gurlek A, Berker M (2016) Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases. Acta Neurochir 158(5):933–942. doi: https://doi.org/10.1007/s00701-016-2762-z
doi: 10.1007/s00701-016-2762-z
pubmed: 26970763
Kars M, Pereira AM, Smit JW, Romijn JA (2009) Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med 20(4):387–393. doi: https://doi.org/10.1016/j.ejim.2008.11.012
doi: 10.1016/j.ejim.2008.11.012
pubmed: 19524180
Zhao Y, Jin D, Lian W et al (2019) Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old. Medicine 98(6):e14380. doi: https://doi.org/10.1097/MD.0000000000014380
doi: 10.1097/MD.0000000000014380
pubmed: 30732174
pmcid: 6380812
Vale FL, Deukmedjian AR, Hann S, Shah V, Morrison AD (2013) Medically treated prolactin-secreting pituitary adenomas: when should we operate? Br J Neurosurg 27(1):56–62. doi: https://doi.org/10.3109/02688697.2012.714817
doi: 10.3109/02688697.2012.714817
pubmed: 22938595
Vroonen L, Jaffrain-Rea M-L, Petrossians P et al (2012) Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167(5):651–662. doi: https://doi.org/10.1530/EJE-12-0236
doi: 10.1530/EJE-12-0236
pubmed: 22918301
Ioachimescu AG, Fleseriu M, Hoffman AR, Vaughan TB, Iii, Katznelson L (2019) Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol 180(1):31–40. doi: https://doi.org/10.1530/EJE-18-0682
doi: 10.1530/EJE-18-0682
pubmed: 30400048
Bloomgarden E, Molitch ME (2014) Surgical treatment of prolactinomas: cons. Endocrine 47(3):730–733. https://doi.org/10.1007/s12020-014-0369-9
doi: 10.1007/s12020-014-0369-9
pubmed: 25112227
Mohan N, Chia YY, Goh GH, Ting E, Teo K, Yeo TT (2017) Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective. BMJ Case RepDoi. https://doi.org/10.1136/bcr-2017-220971
doi: 10.1136/bcr-2017-220971
Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S (1984) Necrotic changes in prolactinomas after long term administration of bromocriptine*. J Clin Endocrinol Metabol 59(3):463–470. https://doi.org/10.1210/jcem-59-3-463
doi: 10.1210/jcem-59-3-463
Takahashi T, Kuwayama A, Katoh T, Kageyama N (1986) Histological changes and operative findings of pituitary adenomas after bromocriptine treatment. Nihon Naibunpi Gakkai Zasshi 62(12):1336–1351. doi: https://doi.org/10.1507/endocrine1927.62.12_1336
doi: 10.1507/endocrine1927.62.12_1336
pubmed: 3817228
Zygourakis CC, Imber BS, Chen R et al (2017) Cost-effectiveness analysis of surgical versus medical treatment of prolactinomas. J Neurol Surg B Skull Base 78(2):125–131. https://doi.org/10.1055/s-0036-1592193
doi: 10.1055/s-0036-1592193
pubmed: 28321375